Clinical Research Of Anti-VEGF Drugs For The Treatment Of Branch Retinal Vein Occlusion

OBJECTIVE To observe the effects of intravitreous injection with Conbercept and Ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion.METHODS The study observed 42 eyes of 42 patients with macular edema secondary to branch retinal vein occlusion(BRVO),including 23 males and 19 females,and the age ranged from 43—80years old.22 eyes received intravitreal conbercept of 0.5 mg(group A)and 20 eyes received intravitreal ranibizumab 0.5 mg(group B).The Early treatment diabetic retinopathy study(ETDRS)protocol,traocular pressure(IOP),slit 1amp,central retinal thickness(CRT)and fluorescein fundus angiography(FFA)were observed before treatment,and1 month,2 months,3 months and 6 months after treatment.RESULTS There were significantly difference in ETDRS and CMT of group A(t=9.60,t=7.42,P?0.05)and group B(t=14.25,t=9.54,P?0.05)between before and after treatment.The mean numbers of injections were 3.73±7.01(A)and 3.10±1.02(B)during the 6 months.In both groups,the numbers of injections at 6 months was not related to ETDRS(r=0.374,r=0.381,P>0.05)and CRT(r=0.439,r=0.326,P>0.05)at baseline.The numbers of injections was related to age in group A(r=0.471,P?0.05)but not was related to age in group B(r=0.439,P>0.05).There were significantly difference between the two group in the numbers of injections(t=2.22,P?0.05).CRT at 6 months was not related to ETDRS and CRT at baseline in group A(r=0.488,r=0.385,P>0.05).About group B,CRT at 6 months was related to CRT at baseline(r=0.387,P?0.05),but not related to ERTDS at baseline(r=0.525,P>0.05).In both group,CRT at 6 months was related to age(r=0.0.497,r=0.571,P?0.05).Several baseline factors including high blood pressure,diabetes and cerebral infarction are not associated with CRT outcomes in both group(r=0.254,r=0.241,r=0.325,P>0.05)、(r=0.053,r=0.029,r=0.289,P>0.05).No systemic or ocular serious adverse events were observed during the follow-up period.CONCLUSIONS Intravitreous injections of conbercept and ranibizumab had the same effective to the treatment of branch retinal vein occlusion.Both of them can improve the visual function and reduce the degree of CRT in patients.The mean numbers of injections with ranibizumab were less than that of conbercept in the treatment of BRVO.The CRT outcomes are associated with age,and not associated with several baseline factors including high blood pressure,diabetes and cerebral infarction.